Mobile App

Google Play Apple Store
Independent Conference Coverage from the American College of Chest Physicians (CHEST) Annual Meeting 2024*
AMA/ANCC/ACPE Activity
Despite dramatic advances in the development of treatments for pulmonary arterial hypertension (PAH), it remains a chronic life-threatening illness for which there is no cure. Advances in knowledge within the field are eagerly anticipated.

These educational Clinical Clips will spotlight important research into the basic science, diagnosis, treatment, and medical management of patients with PAH based on data presented at the American College of Chest Physicians (CHEST) Annual Meeting in Boston, MA October 6-9, 2024.
Review this activity and claim AMA, ANCC, or ACPE credits/contact hours after completion of a brief pretest and post-test/evaluation



 
Ioana Preston, MD Ioana Preston, MD
Associate Professor of Medicine
Tufts University School of Medicine

*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the American College of Chest Physicians (CHEST) Annual Meeting 2024.
20
Supported by independent educational grants from United Therapeutics, a public benefit company, Bayer U.S.; Merck & Co., Inc., Rahway, NJ, USA; and Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson

Launch Date: October 7, 2024
Release Date: October 7, 2024
Expiration Date: September 30, 2025

Mini Module
7802
ClinicalClips_PAH_1150x108.png
False
Pulmonology

CookieConsent

Change Settings